Drug Approval | September 11, 2024
USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The recent inspection covered both cGMP and PAI processes
The patient has been isolated in a designated hospital and is currently stable
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Subscribe To Our Newsletter & Stay Updated
